Training Example: EPCLUSA – Review the Data, Give Your Score & Compare to the Real AI Evaluation

Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…

EPCLUSA

(https://epclusa.com) 📸 Data Snapshot: May 30, 2026

Analyze the raw signals below. How would a machine score this business’s credibility?

Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.

🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE EPCLUSA® (sofosbuvir/velpatasvir) A Hep C Treatment Option | Patient Site (https://epclusa.com)
Title

EPCLUSA® (sofosbuvir/velpatasvir) A Hep C Treatment Option | Patient Site

Meta

Discover EPCLUSA® (sofosbuvir/velpatasvir), a prescription medicine used to treat chronic Hep C. See Important Safety Information including Important Warning.

H2 Treat hepatitis C your way
H4 Find confidence in curing Hep C with EPCLUSA on your To-Day List.
H5 Have Medicaid?
H5 Hep C may lead to serious liver damage.
H5 One pill, once a day, one step closer to cure.
H5 EPCLUSA can treatHep C
H5 Questions about Hep C treatment?
H6 Find confidence in curing Hep C with EPCLUSA on your To-Day List.
H6 Find a healthcare provider
H6 Cure Hep C while in recovery
NAV_HEADER_HEADING_REPEATED_FOOTER Why Treat Hep C Virus With EPCLUSA®? | Patient Site (https://epclusa.com/why-treat-hep-c/)
Title

Why Treat Hep C Virus With EPCLUSA®? | Patient Site

Meta

Learn about the urgency & importance of treating your Hepatitis C. Read how to treat Hep C with EPCLUSA® & Important Safety Information, including Important Warning.

H4 Watch this video to learn more
H4 Quick facts about hepatitis C:
H4 Liver damage over time
H4 Hep C can be cured with EPCLUSA, even in recovery
H5 How many people have Hep C
H5 How Hep C can be spread
H5 Hep C symptoms
H5 Can be taken with many medication-assisted treatments including buprenorphine/naloxone, methadone, and naltrexone
H5 Can be taken whether you're in recovery or not
H5 Works with your schedule
H5 One pill, once a day, for 12 weeks. In a regular pill bottle small enough to fit in your pocket
H6 Find a healthcare provider
H6 Learn more about EPCLUSA side effects
NAV_HEADER_HEADING_REPEATED_FOOTER Why Choose EPCLUSA® as Your Treatment for Hep C | Patient Site (https://epclusa.com/why-epclusa/)
Title

Why Choose EPCLUSA® as Your Treatment for Hep C | Patient Site

Meta

EPCLUSA® (sofosbuvir/velpatasvir) may be a treatment choice for adults living with Chronic Hep C. Read Important Safety Information including Important Warning.

H5 One pill, once a day, one step closer to cure.
H5 Have Medicaid?
H5 Being “ready” to cure Hep C looks different for everyone.
H5 Can be taken with many forms of birth control.†
H5 FDA approved for use in children 3 years of age and older.
H6 Find a healthcare provider
H6 Learn more about EPCLUSA side effects
NAV_HEADER_HEADING_REPEATED_FOOTER EPCLUSA® (sofosbuvir 400 mg/velpatasvir 100 mg) Resources | Patient Site (https://epclusa.com/helpful-resources/)
Title

EPCLUSA® (sofosbuvir 400 mg/velpatasvir 100 mg) Resources | Patient Site

Meta

Find downloadable resources to help you speak to a healthcare provider. Watch the EPCLUSA® (sofosbuvir/velpatasvir) Hep C commercial to learn more. Read Important Safety Information Including Important Warning.

H5 EPCLUSA Patient Brochure
H5 EPCLUSA Patient Starter Kit
H5 Caregiver Booklet
H5 EPCLUSA Patient Brochure – Spanish
H5 EPCLUSA Patient Starter Kit – Spanish
H5 Financial Resources
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE · THIN (https://epclusa.com) EPCLUSA® (sofosbuvir/velpatasvir) A Hep C Treatment Option | Patient Site

                            
0 chars
SUB-PAGE · THIN (https://epclusa.com/why-treat-hep-c/) Why Treat Hep C Virus With EPCLUSA®? | Patient Site

                            
0 chars
SUB-PAGE · THIN (https://epclusa.com/why-epclusa/) Why Choose EPCLUSA® as Your Treatment for Hep C | Patient Site

                            
0 chars
SUB-PAGE · THIN (https://epclusa.com/helpful-resources/) EPCLUSA® (sofosbuvir 400 mg/velpatasvir 100 mg) Resources | Patient Site

                            
0 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
0Review mentions (all pages)
0External proof links (all pages)
PageReviewsProof links
/ (home) 0 0
/why-treat-hep-c/ 0 0
/why-epclusa/ 0 0
/helpful-resources/ 0 0
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage — no schema detected (entity gap)
/why-treat-hep-c/ — no schema detected (entity gap)
/why-epclusa/ — no schema detected (entity gap)
/helpful-resources/ — no schema detected (entity gap)

Your Diagnosis

Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.

Information Density 0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence 0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof 0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint 0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority 0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score 0 / 100
💡 Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)

These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.

Information Density

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Semantic Alignment

Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.

Trust & Proof

Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.

Commodity Fingerprint

Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.

Identity & Authority

Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.

Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.

B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS

Based on 784 businesses audited.

BS Detector

Medical Devices, Pharma & Biotech BS: EPCLUSA (epclusa.com)

https://epclusa.com 📍 Industry: Medical Devices, Pharma & Biotech
38 BS / 100

EPCLUSA provides a highly coherent, patient-focused narrative that is low on typical ‘corporate synergy’ BS but high on pharmaceutical gatekeeping. It successfully avoids semantic drift but fails technically on authority through a total absence of structured data and external evidence paths. It is a well-designed marketing tool that prioritizes convenience claims over clinical transparency.

Info Density Power-words vs. Substance ratio.
10
33% BS
Semantic Coherence Homepage promise vs. Sub-page reality.
0
0% BS
Trust & Proof Verifiable evidence vs. Trust Theatre.
11
55% BS
Commodity Fingerprint Detection of industry clichés/templates.
7
47% BS
Identity & Authority Expert verifiability & Schema depth.
10
67% BS

Implement MedicalWebPage and Organization schema_json to establish technical authority and link to the parent company’s sameAs profiles. Replace redundant H6 ‘Find confidence’ tags with specific H2/H3 headings citing clinical trial cure rates (e.g., ‘98% Cure Rate in Clinical Trials’). Add a dedicated ‘Clinical Evidence’ section to the Why Epclusa page with direct outbound links to published peer-reviewed studies on PubMed. Ensure all H1 tags are populated with the specific drug name and primary indication to fix the broken heading hierarchy.

The content perfectly aligns with the Pharmaceutical and Biotech industry. It focuses on a specific therapeutic area (Hepatitis C), mentions specific drug components (sofosbuvir/velpatasvir), and adheres to regulatory-mandated safety information and indications for use.

“The score of 38 reflects a site that is medically substantial but technically weak in the Authority and Trust pillars. The Information Density and Semantic Coherence pillars performed exceptionally well, preventing a higher BS score. The lack of schema and external proof paths are the primary drivers of the final score.”

Verified Analysis Date: May 30, 2026 © 1EuroSEO Independent Evaluator — Non-Sponsored Result
Brand AI Reputation